



BETA DRUGS LIMITED

BDL/PKL/SEC/2018
26th October, 2018

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Outcome of Board Meeting of Beta Drugs Limited-26th October, 2018

With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 26th October, 2018, at 11:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has approved unanimously the following item:

1. To consider and approve the un-audited financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the half year ended 30th September, 2018.

The meeting of the Board of Directors commenced at 11.00 a.m. and concluded at 1.45 p.m.

This is for your information and appropriate dissemination.

Thanking You

Your's faithfully
For Beta Drugs Ltd.


Rajni Brar
Company Secretary

CIN No.: U24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com



BETA DRUGS LIMITED

❖ MANAGEMENT DISCUSSION & ANALYSIS

Beta's total revenues for the first half ended September 30th, 2018 grew by 38.4% to Rs 29.65 crores from Rs 21.43 crores compared with the same period a year ago. This was primarily driven by rise in sales across all geographies. In addition, the company continued to increase its market share in the domestic oncology segment. Beta also added some marquee names to its clients list for its CRAMS business and continued to expand its presence across corporate hospitals in India.

EBITDA margins for the first half ended September 30th, 2018 rose by 65 basis points to 19.74% due to cost efficiencies as compared to full year fiscal year 2018, ended March.

❖ GUIDANCE FOR SECOND HALF

Beta expects sales for the second half to be in the range of Rs 35 – Rs 37 crore with net profit to be in the range of Rs 4.6 to 4.65 crore. Beta expects full year profit to be in the range Rs 8.02 – Rs 8.07 crore.

Beta expects to close its acquisition of Adley Formulation in third quarter of current fiscal which would further give boost to both its topline and bottom line.

For Beta Drugs Ltd.

V.K. Bhatia
Managing Director



CIN No.: U24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com



"A Peer Review Firm"

KALRA RAI & ASSOCIATES CHARTERED ACCOUNTANTS

GSTIN : 04AAFFK0327HIZT

Ref. No.

Dated

Auditors Limited Review Report on Half Yearly Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors
Beta Drugs Limited
Village Nandpur,
Lodhimajra Road,
Tehsil. Baddi,
Distt. Solan,
(H.P.) 173205,
India.

We have reviewed the accompanying standalone financial results of Beta drugs limited ("The Company") for the half year ended on 30th September, 2018 attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These half yearly standalone financial results have been prepared on the basis of the standalone financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our review of such financial statements, which have been prepared in accordance with the Accounting Standards notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our review in accordance with the revised standard on review engagements (SRE) 2400, "Engagements to review Financial Statements", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance about whether the financial statements are free of material misstatements. A review is limited preliminary to inquiries of company professionals and analytical procedures applied to the financial data and thus provide less assurance than an Audit. We have not performed an Audit and accordingly, we do not express an Audit opinion.

Management has informed us that the Gratuity and leave Encashment has not been provided in the books of accounts as required by Accounting Standard AS 15. "Employees benefits (Revised 2005)", notified by the central Government under the Companies (Accounting Standards) Rules, 2006. The amount of such liability till 31.03.2018 was Rs 4,44,513 /- however, the amount for the period ended 30-Sep-2018 cannot be quantified as the company has not got the actuarial valuation certificate from an



actuary. Thus to that extent the profit for the period ended 30-Sep-2018 is overstated and liabilities are understated.

Based on our review, expect for the effects of the overstatements of profits due to non provision of Gratuity and leave Encashment described in the previous paragraph, nothing has come to our attention that causes us to believe that the accompanying financial results do not give a true and fair view in accordance with the aforesaid Rules,2006.

Further, the cost of direct expenses are shown as cost of material consumed for better presentation in financial statements in accordance with accounting standard -1.

Further, due to the recent judicial pronouncement of Hon'able Supreme Court in the case of CIT VS Classic Binding Industries , the MAT Credit figure of the previous year be revised and the impact of the same be adjusted by reducing the Reserve & Surplus. The amount of MAT adjusted is Rs. 2,84,89,169 /-

Further, read with paragraph 1above, we report that the figures for the half year ended 30th September,2018 represents the derived figures between the audited figures in respect of the financial year ended March 31,2018 and the unaudited half yearly figures as on 30th September,2017.

As per regulation 33(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015 the limited review report submitted to the stock exchange on a quarterly or annual basis are to be given only by an auditor who as subjected himself to the peer review process of ICAI and holds a valid certificate issued by the Peer Review Board of the Institute. We hereby bring it to your notice that the period under review is prior to the listing of the Equity Shares on the NSE Emerge (SME segment) and further we are in process of getting enrolled with the Peer Review Board of ICAI.

For KALRA RAI AND ASSOCIATES

Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438

Place : Panchkula.
Date : 26th oct,2018

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. U24230HP2005PLC028969

Unaudited Financial Results for the half year ended on 30th Sep 2018

Particulars	6 Months Ended on 30/09/2017 (Audited)	6 Months Ended on 31/03/2018 (Audited)	6 Months Ended on 30/09/2018 (Unaudited)	Year Ended on 31/03/2018 (Audited)
I. Revenue From Operations				
II. Other Income	214,040,052.62	291,627,818.64	293,479,497.77	505,667,871.26
	217,635.73	2,226,262.53	2,991,409.00	2,443,898.26
III. Total Revenue (I+II)	214,257,688.35	293,854,081.17	296,470,906.77	508,111,769.52
IV. Expenses				
a) Cost Of Materials Consumed	126,433,132.73	158,994,128.77	166,733,706.25	283,620,299.50
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods	512,248.00	(3,906,521.00)	2,433,727.45	(1,587,311.00)
d) Finance Costs	4,129,601.00	6,013,389.07	4,447,079.28	10,142,990.07
e) Employee benefit expenses	25,570,849.14	31,439,214.63	35,896,375.01	57,010,063.77
f) Depreciation & amortisation expenses	6,849,251.61	11,657,454.95	11,917,127.65	18,506,706.56
g) Other expenses	46,281,606.11	25,780,494.46	32,875,194.40	72,062,100.57
Total Expenses	209,776,688.59	229,978,160.88	254,303,210.04	439,754,849.47
V. Profit before exceptional and extraordinary items and tax (III-IV)	4,480,999.76	63,875,920.29	42,167,696.73	68,356,920.05
VI. Exceptional Items	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	4,480,999.76	63,875,920.29	42,167,696.73	68,356,920.05
VIII. Extraordinary Items	-	-	-	-
IX. Profit before tax (VII-VIII)	4,480,999.76	63,875,920.29	42,167,696.73	68,356,920.05
X. Tax Expenses				
a) Current year tax	-	-	8,868,175.74	-
b) MAT credit/Deferred tax	360,127.60	360,127.60	(933,050.00)	720,255.20
XI. Profit (Loss) for the period from continuing operations (IX-X)	4,120,872.16	63,515,792.69	34,232,570.99	67,636,664.85
XII. Profit (Loss) from discounting operations				
XIII. Tax expenses of discounting operations				
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)				
XV. Net Profit/(Loss) for the period (XI+XIV)	4,120,872.16	63,515,792.69	34,232,570.99	67,636,664.85
XVI. Earning per share				
a) Basic	4.08	7.34	3.96	7.82
b) Diluted	0.48	7.34	3.96	7.82
XVIII. Paid up equity share captial	10,100,000.00	86,495,000.00	86,495,000.00	86,495,000.00
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	54,730,140.12	242,324,139.79	277,457,242.25	242,324,139.79

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 26th Oct 2018.

2 The company is engaged in single business segment i.e. Pharmaceutical.

3 Figures are regrouped/rearranged, whenever considered necessary.

For **KALRA RAI AND ASSOCIATES**

Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA

PARTNER

Membership No. : 087438

Place : Chandigarh

Date : 26.10.2018

For and on Behalf of Board of Directors

VINAY KUMAR BATRA

MANAGING DIRECTOR

DIN : 01083215

NEERAJ BATRA

WHOLE TIME DIRECTOR

DIN : 02229217

RAJNI BRAR

COMPANY SECRETARY

ACS24684

JAYANT KUMAR

CFO

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. U24230HP2005PLC028969

Statement Of Assets & Liabilities For the half year ended 30th September, 2018

Particulars	As at 30th Sep, 2018	As at 31 March, 2018
	Amount in Rs.	Amount in Rs.
1. EQUITY AND LIABILITIES		
(A) Shareholder's Funds		
(a) Share Capital	86,495,000.00	86,495,000.00
(b) Reserves and Surplus	248,067,541.78	242,324,139.79
(c) Money received against share warrants		
Sub-total-Shareholders' funds	334,562,541.78	328,819,139.79
(B) Non- Current Liabilities		
(a) Long-term borrowings	36,363,210.55	27,515,726.91
(b) Deferred tax liabilities (Net)	566,625.95	1,499,675.95
(c) Other Long term liabilities	2,500,000.00	2,500,000.00
(d) Other Long term Provisions		
Sub-total-Non- current liabilities	39,429,836.50	31,515,402.86
(C) Current Liabilities		
(a) Short-term borrowings	39,177,918.85	35,865,012.02
(b) Trade Payable	113,864,676.75	61,058,593.71
(c) Other current liabilities	27,887,981.56	35,289,931.92
(d) Short-term provisions	8,868,175.74	3,254,956.00
Sub-total-current liabilities	189,798,752.90	135,468,493.65
TOTAL - EQUITY AND LIABILITIES	563,791,131.18	495,803,036.30
2. ASSETS		
(A) Non-current assets		
(a) Fixed assets		
(i) Property, Plant & Equipment	127,969,766.82	131,870,936.38
(ii) Intangible assets		
(iii) Capital work-in-progress	68,228,055.34	13,474,652.00
(b) Long Term Loan & Advance	100,000.00	27,216,624.00
(c) Other Non Current Assets		
(d) Deferred tax Assets		
Sub-total-Non-current assets	196,297,822.16	172,562,212.38
(B) Current Assets		
(a) Inventories	37,160,292.83	28,034,802.00
(b) Trade receivable	187,171,064.35	144,422,475.31
(c) Cash and bank balance	70,275,456.41	119,066,796.46
(d) Short-term loan and advances	41,991,180.00	14,129,962.48
(e) Other current assets	30,895,315.43	17,586,787.67
Sub-total-current assets	367,493,309.02	323,240,823.92
TOTAL - ASSETS	563,791,131.18	495,803,036.30

The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 26th Oct 2018.

The company is engaged in single business segment i.e. Pharmaceutical.

Figures are regrouped/rearranged, whenever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)


For and on Behalf of Board of Directors


LAJPAT RAI KALRA
PARTNER

Membership No. : 087438

Place : Chandigarh

Date : 26.10.2018


VIJAY KUMAR BATRA
 MANAGING DIRECTOR
 DIN : 01083215


NEERAJ BATRA
 WHOLE TIME DIRECTOR
 DIN : 02229217